• KOL
    • KOLs Community
    • Ulcerative
    • Ulcerative Colitis
    • Severine Ara Vermeire
    • Severine ARA VERMEIRE

      Severine ARA VERMEIRE

      Department of Gastroenterology and Hepatology, University Hospitals Leuven, Leuven, Belgium | Department of Chronic Diseases Metabolism and Ageing, Catholic University Leuven, ...



      KOL Resume for Severine ARA VERMEIRE


      Department of Gastroenterology and Hepatology, University Hospitals Leuven, Leuven, Belgium


      Gastroenterology and Hepatology, University Hospitals, KU Leuven, Leuven, Belgium

      KU Leuven - Department of Chronic Diseases, Metabolism, and Ageing


      IBD Leuven, 1University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium

      Department of Chronic Diseases, Metabolism and Ageing, Translational Research Center for Gastrointestinal Disorders (TARGID)

      European Reference Network on Hepatological Diseases


      Department of Gastroenterology and Hepatology, Translational Research in Gastrointestinal Disorders, UZ Leuven, KU Leuven



      Severine ARA VERMEIRE: Influence Statistics

      Sample of concepts for which Severine ARA VERMEIRE is among the top experts in the world.
      Concept World rank
      vdz assay #1
      colitis based #1
      assay detected samples #1
      xap patients #1
      crohns disease elisa #1
      75 225 pf00547659 #1
      dlg5 card protein #1
      age ifx #1
      ace2 ileum #1
      26 weeks vitamin #1
      10 chromosomal regions #1
      endoscopic remission hospitalization #1
      problem immunogenicity #1
      ioibd technical review #1
      pharmacokinetics immunogenicity #1
      presence ileal #1
      vedolizumab pouch construction #1
      trem1 tnf #1
      cd14 trem1 expression #1
      2‐year data analysis #1
      ifx #1
      q8w enrolment #1
      noninvasive models patients #1
      heterogeneity clinical traits #1
      induction studies placebo #1
      ata formation 95 #1
      touchstone study #1
      drug‐sensitive #1
      detection infliximab #1
      citrullination nets #1
      week classic #1
      extended access programme #1
      infliximab treated patients #1
      response ibd patients #1
      uai data #1
      blood mucosal expression #1
      turandot #1
      60 practices eci #1
      sustained clinical #1
      oral inhibitor patients #1
      6 months week #1
      90 7 models #1
      ibd ifx therapy #1
      card protein dlg5 #1
      elisa remicade remicade #1
      remission colon tissues #1
      qol ibdq #1
      dosing frequency q8w #1
      ferring janssen #1
      patients mobilisation #1


      Prominent publications by Severine ARA VERMEIRE

      KOL-Index: 21441

      BACKGROUND: Tofacitinib, an oral, small-molecule Janus kinase inhibitor, was shown to have potential efficacy as induction therapy for ulcerative colitis in a phase 2 trial. We further evaluated the efficacy of tofacitinib as induction and maintenance therapy.

      METHODS: We conducted three phase 3, randomized, double-blind, placebo-controlled trials of tofacitinib therapy in adults with ulcerative colitis. In the OCTAVE Induction 1 and 2 trials, 598 and 541 patients, respectively, who had ...

      Known for Tofacitinib Placebo | Ulcerative Colitis | Maintenance Therapy | Octave Induction | 8 Weeks
      KOL-Index: 19205

      BACKGROUND: The global prevalence of ulcerative colitis is increasing, and induction and maintenance of remission is a crucial therapeutic goal. We assessed the efficacy and safety of filgotinib, a once-daily, oral Janus kinase 1 preferential inhibitor, for treatment of ulcerative colitis.

      METHODS: This phase 2b/3, double-blind, randomised, placebo-controlled trial including two induction studies and one maintenance study was done in 341 study centres in 40 countries. Eligible patients ...

      Known for Ulcerative Colitis | Maintenance Study | Clinical Remission | Induction Studies | Filgotinib Treatment
      KOL-Index: 18965

      BACKGROUND & AIMS: Histamine sensitizes the nociceptor transient reporter potential channel V1 (TRPV1) and has been shown to contribute to visceral hypersensitivity in animals. We investigated the role of TRPV1 in irritable bowel syndrome (IBS) and evaluated if an antagonist of histamine receptor H1 (HRH1) could reduce symptoms of patients in a randomized placebo-controlled trial.

      METHODS: By using live calcium imaging, we compared activation of submucosal neurons by the TRPV1 agonist ...

      Known for Patients Ibs | Histamine Receptor | Abdominal Pain | Irritable Bowel Syndrome | Submucosal Neurons
      KOL-Index: 17380

      BACKGROUND & AIMS: The efficacy and safety of vedolizumab, a humanized immunoglobulin G1 monoclonal antibody against the integrin α4β7, were demonstrated in multicenter, phase 3, randomized, placebo-controlled trials in patients with moderately to severely active ulcerative colitis (UC) or Crohn's disease. We analyzed data from 1 of these trials to determine the effects of vedolizumab therapy in patients with UC, based on past exposure to anti-tumor necrosis factor-α (TNF) ...

      Known for Placebo Patients | Ulcerative Colitis | Efficacy Vedolizumab | Maintenance Therapy | Tnf Antagonists
      KOL-Index: 16848

      BACKGROUND: Episodic infliximab (IFX) treatment is associated with the formation of antibodies to IFX (ATIs) in the majority of patients, which can lead to infusion reactions and a shorter duration of response. Concomitant use of immunosuppressives (IS) reduces the risk of ATI formation.

      AIMS AND METHODS: To investigate which of the IS-that is, methotrexate (MTX) or azathioprine (AZA)-is most effective at reducing the risk of ATI formation, a multicentre cohort of 174 patients with ...

      Known for Patients Atis | Immunosuppressive Therapy | Aza Mtx | Ifx Formation | Infliximab Infusions
      KOL-Index: 16098

      The advent of biological therapy has revolutionized inflammatory bowel disease (IBD) care. Nonetheless, not all patients require biological therapy. Selection of patients depends on clinical characteristics, previous response to other medical therapy, and comorbid conditions. Availability, reimbursement guidelines, and patient preferences guide the choice of first-line biological therapy for luminal Crohn's disease (CD). Infliximab (IFX) has the most extensive clinical trial data, but ...

      Known for Biological Therapy | London Position Statement | Monoclonal Antibodies | Ifx Patients | Loss Response
      KOL-Index: 16017

      BACKGROUND: Crohn's disease and ulcerative colitis are the two major forms of inflammatory bowel disease; treatment strategies have historically been determined by this binary categorisation. Genetic studies have identified 163 susceptibility loci for inflammatory bowel disease, mostly shared between Crohn's disease and ulcerative colitis. We undertook the largest genotype association study, to date, in widely used clinical subphenotypes of inflammatory bowel disease with the goal of ...

      Known for Ulcerative Colitis | Genetic Association | Disease Location | Inflammatory Bowel | Treatment Strategies
      KOL-Index: 15586

      BACKGROUND & AIMS: Mucosal healing is an independent predictor of sustained clinical remission in patients with ulcerative colitis (UC) treated with infliximab. We investigated whether infliximab concentrations during induction therapy are associated with short-term mucosal healing (STMH) in patients with UC.

      METHODS: We performed a retrospective, single-center analysis of data collected from a tertiary referral center from 101 patients with UC who received scheduled induction therapy ...

      Known for Induction Therapy | Mucosal Healing | Ulcerative Colitis | Patients Stmh | Infliximab Concentration
      KOL-Index: 15421

      BACKGROUND & AIMS: Vedolizumab is a gut-selective monoclonal antibody for the treatment of moderately to severely active Crohn's disease (CD). We performed a prospective study of endoscopic, radiologic, and histologic healing in patients with CD who received vedolizumab therapy.

      METHODS: We performed a phase 3b, open-label, single-group study of 101 patients with at least 3 months of active CD (a CD Activity Index [CDAI] score of 220-450, a simple endoscopic score for CD [SES-CD] of 7 or ...

      Known for Histologic Healing | Endoscopic Remission | Vedolizumab Patients | Active Crohn | Week 52
      KOL-Index: 15386

      BACKGROUND: Filgotinib (GLPG0634, GS-6034) is a once-daily, orally administered, Janus kinase 1 (JAK1)-selective inhibitor. The FITZROY study examined the efficacy and safety of filgotinib for the treatment of moderate-to-severe Crohn's disease.

      METHODS: We did a randomised, double-blind, placebo-controlled phase 2 study, which recruited patients from 52 centres in nine European countries. We enrolled eligible patients aged 18-75 years with a documented history of ileal, colonic, or ...

      Known for Clinical Remission | Filgotinib Placebo | Crohn Disease | Week Patients | Phase 2
      KOL-Index: 15332

      BACKGROUND: Ustekinumab, a monoclonal antibody to the p40 subunit of interleukin-12 and interleukin-23, was evaluated as an intravenous induction therapy in two populations with moderately to severely active Crohn's disease. Ustekinumab was also evaluated as subcutaneous maintenance therapy.

      METHODS: We randomly assigned patients to receive a single intravenous dose of ustekinumab (either 130 mg or approximately 6 mg per kilogram of body weight) or placebo in two induction trials. The ...

      Known for Maintenance Therapy | Patients Placebo | Remission Week | Intravenous Ustekinumab | Induction Trials
      KOL-Index: 15223

      BACKGROUND & AIMS: The addition of immunomodulators increases the efficacy of maintenance therapy with infliximab for up to 1 year in patients with Crohn's disease who have not been previously treated with immunomodulators. However, there are questions about the effect of withdrawing immunomodulator therapy from these patients. We studied the effects of treatment with infliximab and immunomodulators (co-treatment) and then immunomodulator withdrawal on long-term outcomes of patients, as ...

      Known for Infliximab Patients | Trough Levels | Immunomodulators Treatment | Crohn Disease | Immunomodulator Therapy
      KOL-Index: 15132

      BACKGROUND & AIMS: Infliximab, a tumor necrosis factor antagonist, is effective for treating patients with Crohn's disease (CD) and ulcerative colitis (UC). We aimed to determine whether dosing based on therapeutic drug monitoring increases rate of remission and whether continued concentration-based dosing is superior to clinically based dosing of infliximab for maintaining remission in patients with CD and UC.

      METHODS: We performed a 1-year randomized controlled trial at a tertiary ...

      Known for Patients Remission | Trough Concentrations | Based Dosing | 37 Μg | Ulcerative Colitis Uc
      KOL-Index: 14936

      BACKGROUND & AIMS: Etrolizumab is a humanized monoclonal antibody against the β7 integrin subunit that has shown efficacy vs placebo in patients with moderate to severely active ulcerative colitis (UC). Patients with colon tissues that expressed high levels of the integrin αE gene (ITGAE) appeared to have the best response. We compared differences in colonic expression of ITGAE and other genes between patients who achieved clinical remission with etrolizumab vs those who did.

      METHODS: We ...

      Known for Ulcerative Colitis | Patients Uc | Clinical Remission | Colon Biopsies | Etrolizumab Treatment
      KOL-Index: 14766

      BACKGROUND: Fecal calprotectin is a marker of inflammation in inflammatory bowel disease (IBD). Since mucosal healing has become a goal of treatment in IBD we examined how reliably calprotectin levels reflect mucosal disease activity.

      METHODS: In all, 126 IBD patients and 32 irritable bowel syndrome (IBS) patients needing colonoscopy delivered a sample of feces prior to the start of bowel cleansing. Besides collection of symptom scores and blood tests, experienced endoscopists recorded ...

      Known for Fecal Calprotectin | Bowel Disease | Surrogate Marker | Endoscopic Lesions | 250 Μg

      Key People For Ulcerative Colitis

      Top KOLs in the world
      William J Sandborn∥
      ulcerative colitis inflammatory bowel disease certolizumab pegol
      JeanFr’ed’eric JeanFrederic
      ulcerative colitis inflammatory bowel disease ibd patients
      Stephen B Hanauer
      ulcerative colitis inflammatory bowel disease certolizumab pegol
      Rutgeerts RUTGEERTS
      ulcerative colitis crohns disease mucosal healing
      Severine ARA VERMEIRE
      ulcerative colitis inflammatory bowel disease mucosal healing
      Schreiber Schreiber
      ulcerative colitis inflammatory bowel disease certolizumab pegol

      Severine ARA VERMEIRE:Expert Impact

      Concepts for whichSeverine ARA VERMEIREhas direct influence:Ulcerative colitis,  Inflammatory bowel disease,  Inflammatory bowel,  Crohns disease,  Crohn disease,  Bowel disease,  Inflammatory bowel diseases,  Mucosal healing.

      Severine ARA VERMEIRE:KOL impact

      Concepts related to the work of other authors for whichfor which Severine ARA VERMEIRE has influence:Inflammatory bowel disease,  Ulcerative colitis,  Gut microbiota,  Ibd patients,  Mucosal healing,  Intestinal inflammation,  Clinical remission.



      Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

      Department of Gastroenterology and Hepatology, University Hospitals Leuven, Leuven, Belgium | Department of Chronic Diseases Metabolism and Ageing, Catholic University Leuven, Leuven, Belgium | Gastroenterology and Hepatology, University Hospitals, K

    Download on the App StoreGet it on Google Play

    Copyright © 2023 - KOL means Key Opinion Leaders .

    KOL does not provide medical advice, diagnosis or treatment.